Home › NCT07416786

Validation of NAD+ Measurements for Human Clinical Studies

Validation of NAD+ Measurements for Human Clinical Studies: Multi-method Inter-laboratory Standardization

Who can join

Ages 18 to 110 · All sexes · Healthy volunteers welcome

* Male or female age18-35 years or 70 years or older, healthy
* if female reproductive potential, use of highly effective contraception (at least 1 month prior to screening and during study participation).
* No known sensitivity to NR
* No use of niacin, blood thinners or chemotherapy agents
* HbA1c below 8.5% and not diabetec requiring insulin.
* Not using/taking corticosteroids
* No laboratory abnormalities indicating significant anemia, bleeding risk, kidney disease, or liver disease
* No contraindication to MRI
* Not Pregnant, lactating, or planning to become pregnant during participation
* Not taking multivitamins or any over-the-counter supplements except calcium and vitamin D (any other supplements - discontinued 2 weeks prior to study participation).
* not taking/ undergoing another investigational drug or other intervention within the past 30 days.

About the study

The purpose of this study is to determine nicotinamide adenine dinucleotide (NAD) levels in healthy adult subjects before and after supplementing with over-the counter nicotinamide riboside (NR) using magnetic resonance spectroscopy (MRS).

What is being tested

• Oral NR Supplementation (dietary supplement)

Sponsor: University of Pennsylvania · Participants: 48 · Started: Sep 1, 2026

Contact the study team

• Damodar Reddy · Phone: 215-898-9357
• Jordan Maddox, BA · Phone: 215-898-3694

Official record on ClinicalTrials.gov — NCT07416786

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.